Our current research findings indicate simultaneous assessment of HER2 and IKZF3 gene status is indispensable for targeted therapy in GC, this can further stratify the risk of GC patients, evaluate patient prognosis and guide subsequent medication plans. This evidence concerns the gene ERBB2 and gastric cancer.